DE CESARIS, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.761
EU - Europa 1.875
AS - Asia 1.434
SA - Sud America 168
AF - Africa 37
OC - Oceania 15
Totale 6.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.730
RU - Federazione Russa 613
IT - Italia 512
CN - Cina 401
SG - Singapore 358
PL - Polonia 267
HK - Hong Kong 216
BR - Brasile 136
VN - Vietnam 133
IE - Irlanda 124
SE - Svezia 100
KR - Corea 97
BD - Bangladesh 82
FR - Francia 59
DE - Germania 49
CH - Svizzera 46
GB - Regno Unito 43
IN - India 29
JO - Giordania 26
FI - Finlandia 23
ID - Indonesia 21
JP - Giappone 19
AU - Australia 15
CA - Canada 15
NL - Olanda 15
AR - Argentina 13
IQ - Iraq 12
CI - Costa d'Avorio 9
ZA - Sudafrica 9
MX - Messico 8
CO - Colombia 7
TR - Turchia 7
NG - Nigeria 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
PH - Filippine 4
PK - Pakistan 4
BJ - Benin 3
EC - Ecuador 3
ES - Italia 3
IL - Israele 3
JM - Giamaica 3
KG - Kirghizistan 3
MA - Marocco 3
MY - Malesia 3
TH - Thailandia 3
UZ - Uzbekistan 3
AT - Austria 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
MT - Malta 2
PE - Perù 2
TN - Tunisia 2
UY - Uruguay 2
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
VE - Venezuela 1
Totale 6.290
Salva come PNG Salva come JPEG
Città #
Santa Clara 663
Ashburn 347
Warsaw 266
Singapore 253
Hong Kong 187
Fairfield 142
San Jose 117
Dublin 115
Seoul 97
Beijing 87
Hefei 78
Woodbridge 73
Chandler 69
Florence 63
Milan 61
Cambridge 60
Seattle 56
Dearborn 50
Houston 50
Council Bluffs 49
Ho Chi Minh City 49
Los Angeles 49
Altamura 48
Buffalo 47
Lawrence 47
Bern 45
Wilmington 45
Chicago 40
New York 39
Moscow 35
Rome 33
Lauterbourg 32
Princeton 26
Munich 24
Hanoi 23
Shanghai 21
The Dalles 20
Boston 19
Kent 18
Tokyo 18
Medford 17
Bologna 15
Naples 15
Ann Arbor 14
Jakarta 14
Melbourne 12
Paris 12
San Diego 12
Salt Lake City 11
Boardman 10
Dallas 10
Figino 10
Mumbai 10
Orem 10
San Mateo 10
São Paulo 10
Turin 10
Abidjan 9
Dong Ket 8
Johannesburg 8
London 8
Miano 8
Clifton 7
Guangzhou 7
Haiphong 7
Helsinki 7
Lappeenranta 7
Palermo 7
Chennai 6
Fontebuona 6
Prato 6
Shenzhen 6
Venice 6
Abuja 5
Baghdad 5
Bengaluru 5
Da Nang 5
Denver 5
Jacksonville 5
Malton 5
Nanjing 5
Padua 5
Ravenna 5
Thiene 5
Toronto 5
Turku 5
Andover 4
Ardea 4
Atlanta 4
Elk Grove Village 4
Frankfurt am Main 4
Hangzhou 4
Manchester 4
Medellín 4
Memphis 4
Newark 4
Ninh Bình 4
Pisa 4
Pontassieve 4
Poplar 4
Totale 3.997
Salva come PNG Salva come JPEG
Nome #
Migraine-provoking substances evoke periorbital allodynia in mice 287
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score 266
Transient receptor potential channels as novel drug targets in respiratory diseases. 262
Protocol and methods for testing the efficacy of well-being therapy in chronic migraine patients: a randomized controlled trial 248
Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series 247
Mental Pain Questionnaire: An item response theory analysis 232
TRPA1 and other TRP channels in migraine 222
Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura 206
Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study 203
Chronic headaches and medication overuse 201
Mental Pain Questionnaire: Clinimetric Properties of a Potential Global Person‐Centred Outcome Measure 191
Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: A post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial 190
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study 187
Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses 180
Acute and chronic triptan exposure neither alters rodent cerebral blood flow nor worsens ischemic brain injury 178
Criterion-related validity in a sample of migraine outpatients: The diagnostic criteria for psychosomatic research 174
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ) 173
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine 162
Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment 160
Migraine Models 157
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study 157
Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine 156
Emerging Pharmacological Treatments for Migraine in the Pediatric Population 153
Epidemiology and determinants of chronic migraine: A real-world cohort study, with nested case-control analysis, in primary care in Italy 146
Mental pain and pain-proneness in migraine subjects: Results from the PAINMIG cohort-study 144
Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RICe) 144
Migraine during covid-19: Data from second wave pandemic in an Italian cohort 142
The role of TRP ion channels in migraine and headache 135
COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report 123
Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany 122
Mental pain as a global person-centred outcome measure 121
Multi-domain destructuring in the early phases of psychosis: a multicentric phenomenological and psychometric case-control study 114
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study 109
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine 107
Placebo Effect of Verbal Instructions Coupled with Pharmacological Treatment: Results from a Randomized Controlled Trial in Migraine Patients 55
Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial 47
Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss 45
The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis 37
Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis 35
Corticosteroid-dependent increased expression of CGRP and its receptor subunits within the rodent trigeminal ganglion does not prompt cephalic allodynia 33
TRPS and Migraine 32
Migraine is a high prevalence disorder which affects a significant proportion of the general population, especially women during their central and more productive time of the life, thus causing severe disability. The genetic basis of the disease is unknown and the mechanism is poorly understood. The possibility that following a perturbation in the central nervous system, and particularly in the brainstem, trigeminal neurons become hyperexcitable and produce an uncontrolled release of sensory neuropeptides which eventually results in arterial vasodilatation and neuronal sensitization, has been gaining credit from studies in experimental animals and humans. In particular, experimental and clinical data with antagonists of the calcitonin gene-related peptide (CGRP) propose this molecule and its receptor as a major target for migraine treatment. 25
Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations 25
Reduction of opioid withdrawal symptoms and opioid-induced hyperalgesia by subcutaneous sumatriptan reveals central neuromodulation 20
Totale 6.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.193
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022197 7 6 7 5 7 5 4 14 15 28 38 61
2022/2023576 45 124 39 15 16 81 66 22 55 17 28 68
2023/2024275 7 28 34 25 18 24 19 57 11 14 31 7
2024/20251.957 60 174 111 255 526 261 51 124 69 152 91 83
2025/20262.376 227 260 160 165 220 73 249 158 185 206 148 325
2026/2027114 114 0 0 0 0 0 0 0 0 0 0 0
Totale 6.353